techMARK (TASX)
- Value:
- 4,381.04
- Change Today:
-
47.43
Latest ShareCast News
UK to give under 40s alternative to AstraZeneca vaccine
By Caoimhe Toman
Date: Friday 07 May 2021
(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.
Meggitt surges as Woodward said to explore possible acquisition
By Michele Maatouk
Date: Friday 07 May 2021
(Sharecast News) - Meggitt shares surged on Friday following a report that US-based Woodward Inc could be looking to buy the London-listed aerospace engineer.
AstraZeneca's Imfinzi demonstrates benefit in combination with antibody
By Josh White
Date: Friday 07 May 2021
(Sharecast News) - AstraZeneca reported on Friday that 'Imfinzi' and tremelimumab with chemotherapy demonstrated an overall survival benefit in the 'POSEIDON' trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.
Price Data
| Price | 4,381.04 |
| Change Today | 47.43 |
| 07-May-21 Close | 4,381.04 |